Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

  • Technology appraisal guidance
  • TA322
  • Published: 
  • Last updated: 
Download guidance (PDF)

Update information

June 2019: Sections 1 and 2 updated to include a new commercial arrangement. Standard text in implementation section updated.

ISBN: 978‑4731‑0751‑9